Sensex
83,294.66 profit arw 479.95 (0.58%)
Nifty
25,713.00 profit arw 141.75 (0.55%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 23-Feb-2026
Corporate News
23-Feb-2026     19:22

Lupin receives European Commission approval for Biosimilar Ranibizumab

Lupin has received the approval from European Commission for its biosimilar ranibizumab, RanluspecTM (for vials and pre-filled syringes), following the recent positive opinion from the Committee for Medicinal Products for Human Use.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. Its indications encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.

Lupin's biosimilar ranibizumab will be commercialized by Sandoz across the European Union (excluding Germany). In France, the product will be commercialized by two companies, Sandoz and Biogaran.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

83,294.66 479.95 (0.58%)

Nifty

25,713.00 141.75 (0.55%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

27,081.92 668.56(2.53%)